SELLAS Life Sciences Group, Inc. — Director's Dealing 2012

Jul 11, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2012-07-10

Reporting Person: Ahn Mark J (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-07-10	Common Stock, par value $0.0001	J	31289	$0.3995	Acquired	92578	Direct

Footnotes

F1: Pursuant to the Issuer's Employee Stock Purchase Plan.